CoChat

An updated patent review of GLP-1 receptor agonists (2020-present)

Lu, Weiwen, Zhou, Zhongbo, Jiang, Neng, Han, Jing · 2023 · Expert Opinion on Therapeutic Patents

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Type 2 diabetes (T2DM) and obesity present significant global health issues, requiring the development of long-lasting and highly effective pharmacotherapies. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) are commonly used for diabetes treatment, their potential for addressing obesity is still being explored. AREAS COVERED: This review offers a comprehensive overview of recently published patents from January 2020 to July 2023, focusing on modified GLP-1RAs, small molecule GLP-1RAs, GLP-1 R-based multi-agonists, GLP-1RA-based fusion proteins, and combination therapies. The patents discussed pertain to the treatment and prevention of diabetes and obesity. Patent searches were conducted using the PATENTSCOPE database of the World Intellectual Property Organization, using the keywords GLP-1, GLP-1/GIP, GLP-1/GCG, and GLP-1/GCG/GIP. EXPERT OPINION: In recent years, patents have emphasized two main goals for developing GLP-1RAs drugs: oral delivery and improved weight reduction effects. To address the growing demand for improved treatments, researchers have focused their efforts on developing GLP-1 R-based multi-agonists, orally administered GLP-1RAs, and combination therapies utilizing GLP-1RAs. These new approaches offer promising benefits, such as improved effectiveness by targeting multiple pathways and reduced side effects. Additionally, the development of new uses, oral forms, and long-lasting preparations will be crucial in shaping the future market potential of GLP-1 drugs.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543776.2023.2274905

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 72 references

Research works printed but not linked: 6

  1. Hanmi Pharm. Co., Ltd. Therapeutic use, for liver disease, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof. WO2020263063. 2020.
  2. Shenzhen Deeply-invasive Biopharmaceutical Co., Ltd. GLP-1R/GCGR/GIPR triple receptor agonist and application thereof. CN114437181A. 2022.
  3. The United Bio-technology (Hengqin) Co., Ltd. Multi-agonist and use thereof. WO2022247701. 2022.
  4. Jiangsu Chinese New Medicine Co., Ltd. GLP-1, GIP and GCG multiple receptor agonist proteins. CN114621327A. 2022.
  5. Heptares Therapeutics Limited. Oral GLP receptor agonists. WO2021186169. 2021.
  6. Janssen Pharmaceutica. Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof. CN112004822A. 2020.

Cited by

See all 17

Metadata

Authors
Lu, W., Zhou, Z., Jiang, N., & Han, J.
Affiliations
  • Guangxi Medical University (CN)
  • Youjiang Medical College for Nationalities (CN)
  • Jiangsu Normal University (CN)
Corresponding author
  • Zhou, Zhongbo
  • Jiang, Neng
  • Han, Jing
Venue
Expert Opinion on Therapeutic Patents
Published
2023-09-02
Volume
33
Issue
9
Pages
597-612
ISSN
  • 1354-3776 (ISSN-L)
  • 1744-7674
OpenAlex
W4387866199
Cited by
17
References
72
Citations by year
2026: 4 · 2025: 9 · 2024: 4
FWCI
0.61
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Therapeutic Patents (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Guangxi Science Fund for Distinguished Young Scholars (2022GXNSFFA035030)
  • Special Funds for Science and Technology Development under the Guidance of the Central Government (ZY20198020)
  • National Natural Science Foundation of China (82173663)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
GLP-1 receptor agonists, type 2 diabetes, obesity, GIP/GLP-1 receptor agonist, combination therapy, sustained drug release, weight loss, pharmaceutical patents
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Patents as Topic, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An updated patent review of GLP-1 receptor agonists (2020-present). https://app.cochat.ai/papers/10.1080/13543776.2023.2274905
The paper
Lu, W., Zhou, Z., Jiang, N., & Han, J. (2023). An updated patent review of GLP-1 receptor agonists (2020-present). Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2023.2274905

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.